We characterized the murine NK cell subsets of the tumor microenvironment （TME） with low expressions of CD16 and NKG2D and investigated the chemokines that deter CD 16~~w NKG2Dl^w subsets. Our results demonstrated t...We characterized the murine NK cell subsets of the tumor microenvironment （TME） with low expressions of CD16 and NKG2D and investigated the chemokines that deter CD 16~~w NKG2Dl^w subsets. Our results demonstrated the activation of primary and KY- 1 NK cell by ligands and found that exogenous CXCL10/interferon-gamma-induced protein 10 （IP-10） and fractalkine （FKN） can up-regulate the expression of CD 16 and NKG2D. Moreover, both IP-10 and FKN are shown to facilitate migration, adhesion and cyto- toxicity of NK cell subsets of the TME, due to the up-regu- lated CD16 and NKG2D. Overall, our data provide a new path by which to enhance murine NK cell cytotoxic potential and improve the quality of NK cells of the TME.展开更多
Background Cyberknife can greatly raise the fractional dose of stereotactic radiosurgery, thus improving its clinical efficacy. We retrospectively analyzed clinical outcomes of brain metastasis treated with Cyberknife...Background Cyberknife can greatly raise the fractional dose of stereotactic radiosurgery, thus improving its clinical efficacy. We retrospectively analyzed clinical outcomes of brain metastasis treated with Cyberknife. Methods We analyzed 40 cases of brain metastases treated with Cyberknife in the Tianjin Cancer Hospital from August 1, 2006 to August 1, 2007, for a total of 68 lesions with maximal diameter of 0.4-7.5 cm （average 1.88 cm）. Total hypofractional radiated dosage was 18-36 Gy （5-25 Gy/F, 1-5 F） by Cyberknife. We evaluated the remission rate of clinical symptoms, correlation factors to new foci, 3-month local control rates, and 3-month and 1-year survival rates. All patients were followed up for more than 14 months. Results After 1 week, clinical remission was 90.0% （36/40）. After 3 months, the local control rate and therapeutic effective rate were 77.9% （53/68） and 94.1% （64/68）, respectively, as observed by cranium augmentation CT or MRI. The three-month, six-month and 1-year survival rates were 97.5% （39/40）, 82.5% （33/40） and 67.5% （27/40）, respectively. Fourteen patients had neopathy outside the original lesion after 3 months. Neopathy was not correlated with age, whole-brain radiotherapy, number of original lesions, maximum diameter of the original lesion, therapeutic dose per fraction, therapeutic frequency or total therapeutic dose. Conclusions Cyberknife got perfect clinical outcomes by higher dosage per fraction. It is an appropriate and valid treatment shortcut for brain metastasis.展开更多
基金the National Natural Science Foundation of China (81171975)the Tianjin Institutes for Basic Sciences (15JCYBJC26900)
文摘We characterized the murine NK cell subsets of the tumor microenvironment （TME） with low expressions of CD16 and NKG2D and investigated the chemokines that deter CD 16~~w NKG2Dl^w subsets. Our results demonstrated the activation of primary and KY- 1 NK cell by ligands and found that exogenous CXCL10/interferon-gamma-induced protein 10 （IP-10） and fractalkine （FKN） can up-regulate the expression of CD 16 and NKG2D. Moreover, both IP-10 and FKN are shown to facilitate migration, adhesion and cyto- toxicity of NK cell subsets of the TME, due to the up-regu- lated CD16 and NKG2D. Overall, our data provide a new path by which to enhance murine NK cell cytotoxic potential and improve the quality of NK cells of the TME.
文摘Background Cyberknife can greatly raise the fractional dose of stereotactic radiosurgery, thus improving its clinical efficacy. We retrospectively analyzed clinical outcomes of brain metastasis treated with Cyberknife. Methods We analyzed 40 cases of brain metastases treated with Cyberknife in the Tianjin Cancer Hospital from August 1, 2006 to August 1, 2007, for a total of 68 lesions with maximal diameter of 0.4-7.5 cm （average 1.88 cm）. Total hypofractional radiated dosage was 18-36 Gy （5-25 Gy/F, 1-5 F） by Cyberknife. We evaluated the remission rate of clinical symptoms, correlation factors to new foci, 3-month local control rates, and 3-month and 1-year survival rates. All patients were followed up for more than 14 months. Results After 1 week, clinical remission was 90.0% （36/40）. After 3 months, the local control rate and therapeutic effective rate were 77.9% （53/68） and 94.1% （64/68）, respectively, as observed by cranium augmentation CT or MRI. The three-month, six-month and 1-year survival rates were 97.5% （39/40）, 82.5% （33/40） and 67.5% （27/40）, respectively. Fourteen patients had neopathy outside the original lesion after 3 months. Neopathy was not correlated with age, whole-brain radiotherapy, number of original lesions, maximum diameter of the original lesion, therapeutic dose per fraction, therapeutic frequency or total therapeutic dose. Conclusions Cyberknife got perfect clinical outcomes by higher dosage per fraction. It is an appropriate and valid treatment shortcut for brain metastasis.
